Arachidonate and docosahexaenoate biosynthesis in various species and compartments in vivo

Impact of linoleic acid intake on arachidonic acid formation and eicosanoid biosynthesis in humans

Long-chain conversion of linoleic acid (LA) and eicosanoid formation was followed in 6 healthy females who were given for 6 weeks liquid formula diets which contained no arachidonic acid but, for 2 weeks each, a LA supply of 0 energy% (en%), 4 en%, and 20 en%, respectively.

RESULTS

higher LA intake resulted in higher LA percentages in investigated lipids, but not in higher amounts of LA present in plasma cholesterol esters or phosphatidylcholine of LDL and HDL comparing liquid formula diet (LFD) 4 and LFD 20. A higher intake of LA resulted in a decrease of arachidonic acid, which was most prominent in HDL phosphatidycholine. Eicosanoids derived from cyclo-oxygenase activity were unchanged by LA intake, while an increase of cytochrome P450-dependent tetranorprostanedioic acid formation was observed with LFD 20.

CONCLUSION

LA intake of 4 en% appears to be a recommendable intake, without signs of stimulated eicosanoid biosynthesis or oxidation.

Docosahexaenoic acid sources for the developing brain during intrauterine life

Docosahexaenoic acid (DHA, 22: 6n-3) and arachidonic acid (AA, 20: 4n-6) provision to the developing fetus, with emphasis towards brain and vascular system growth, is a subject of increasing concern particularly under pathological conditions associated with premature birth or in utero growth restriction following obstruction of the maternal-fetal blood flow. Most of DHA, but also AA accretion under physiological conditions, is maternally dependent and requires adequate maternal nutrition and normally functioning placental-fetal circulation. It has been demonstrated that unlike other fatty acids (FA), DHA is preferentially transported across the placenta into the fetal circulation. The selective transplacental DHA transfer is probably mediated by specific carrier proteins. While some of the latter may be acting in fetal organs, the mechanism(s) for the selective accumulation of DHA in brain is still unknown. The fetal brain and also the fetal liver are capable of producing DHA from linolenic (LnA, 18:3 n-3) acid. How effective this local elongation-desaturation mechanism for DHA provision is and to what degree this route is activated in premature births is not clear. Transfer of DHA via the fetal gastrointestinal tract is an additional route to provide DHA to other fetal organs. As indicated by animal model studies, it holds the potential for DHA supply when the maternal pathway is compromised.

Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man

Alpha-linolenic acid (18:3n-3) is the major n-3 (omega 3) fatty acid in the human diet. It is derived mainly from terrestrial plant consumption and it has long been thought that its major biochemical role is as the principal precursor for long chain polyunsaturated fatty acids, of which eicosapentaenoic (20:5n-3) and docosahexaenoic acid (22:6n-3) are the most prevalent. For infants, n-3 long chain polyunsaturated fatty acids are required for rapid growth of neural tissue in the perinatal period and a nutritional supply is particularly important for development of premature infants. For adults, n-3 long chain polyunsaturated fatty acid supplementation is implicated in improving a wide range of clinical pathologies involving cardiac, kidney, and neural tissues. Studies generally agree that whole body conversion of 18:3n-3 to 22:6n-3 is below 5% in humans, and depends on the concentration of n-6 fatty acids and long chain polyunsaturated fatty acids in the diet. Complete oxidation of dietary 18:3n-3 to CO2 accounts for about 25% of 18:3n-3 in the first 24 h, reaching 60% by 7 days. Much of the remaining 18:3n-3 serves as a source of acetate for synthesis of saturates and monounsaturates, with very little stored as 18:3n-3. In term and preterm infants, studies show wide variability in the plasma kinetics of 13C n-3 long chain polyunsaturated fatty acids after 13C-18:3n-3 dosing, suggesting wide variability among human infants in the development of biosynthetic capability to convert 18:3n-3 to 22:6n3. Tracer studies show that humans of all ages can perform the conversion of 18:3n-3 to 22:6n3. Further studies are required to establish quantitatively the partitioning of dietary 18:3n-3 among metabolic pathways and the influence of other dietary components and of physiological states on these processes.